Germ destroying robots come into their own amid COVID-19 outbreak

Drickus Maartens • March 26, 2020
The Yanex Pulsed-Xenon UV robots deployed in Netcare hospitals use high doses of UV light to destroy viruses, bacteria and fungal spores and disinfect hospital wards, theatres and other spaces within minutes.

Netcare has groundbreaking technologies to strengthen hospital infection prevention and control

With the increase in the spread of the novel coronavirus in South Africa, there has been a surge of interest among the public regarding the measures healthcare providers are taking to prevent the spread of infections, and more specifically COVID-19, in their facilities and in latest technologies that assist in infection prevention and control within hospitals.

“Netcare has for long placed an emphasis on infection prevention measures within its healthcare facilities as a result of the ongoing prevalence of highly infectious viruses such as the coronaviruses, and the so called ‘superbugs’. As a result, we started to acquire super effective germ-destroying robots late in 2017, to further bolster our existing comprehensive disinfection measures,” says the Netcare Group’s chief executive officer, Dr Richard Friedland.  

“Both the Xenex pulsed ultraviolet (UV) robots and Yanex Pulsed-Xenon UV robots deployed in Netcare hospitals use high doses of UV light to destroy viruses, bacteria and fungal spores and disinfect hospital wards, theatres and other spaces within minutes. Now, with the increase in the number of COVID-19 cases in South Africa — which unfortunately won’t be the first, nor likely the last, infectious illness to reach our shores — we are pleased to have opted to invest in innovations such as these germ-eradicating robots. We have also noted that there has been a growing public interest in the technology,” adds Dr Friedland.

According to Dr Friedland, the robots showed impressive infection prevention and control results internationally and during pilot trials at Netcare hospitals in 2017, a first in the country. They have since become an important and established line of defence against viruses, bacteria and fungal spores within Netcare’s healthcare facilities. He says that Netcare currently has 28 robots operating at 22 sites, and will take delivery of a further 13 within the next couple of weeks.

Dr Caroline Maslo, senior clinical advisor at Netcare, says healthcare facilities globally face a daily challenge to prevent the spread of infections within the context of increasing concerns about antibiotic resistance. “Having used the robots in different settings in Netcare facilities, we found that the technology lived up to the impressive results achieved in independent international studies which endorse this method of disinfection.” 

“The Yanex robot, which was designed in Russia, has repeatedly proven itself to be effective and efficient, and this form of disinfection is particularly useful against antibiotic resistant bacteria, and viruses such as COVID-19 which it easily destroys. This new technology does not replace the infection risk management protocols and procedures we already have in place, but is used alongside them as an additional line of defence in our arsenal against potentially harmful germs,” adds Dr Maslo.

She explains that the robots emit UV-C spectrum light, which destroys the DNA of bacteria, viruses and fungi to neutralise them and prevent them from replicating. According to Pharmateknique, marketers of the Yanex disinfection device in South Africa, the system has the ability to destroy an impressive 99,90% of germs on high-touch surfaces and 99.99% of airborne germs. The technology is entirely non-toxic, although the area being disinfected must be vacated during the robot’s cycle, as our eyes are sensitive to the UV light.

“Rigorous disinfection of an area such as a room can be done in just over a minute, which means minimal disruption to busy hospital areas, and the robots can be used 24 hours a day. A more compact and mobile version that folds up into a briefcase size is also available and is used by Netcare 911 to quickly disinfect road and air ambulances and emergency vehicles.”

“The technology has the added advantage in that it requires no water whilst operating, thus rendering it optimally water-wise when compared with other forms of intensive disinfection, and it furthermore uses minimal electricity. Another important benefit is that the robot’s UV light does not result in any residue or potentially harmful by-products, which means it is safe for use in even the most sensitive environments, such as neonatal intensive care units where premature and other compromised babies are cared for.

Each robot deployed in Netcare facilities is connected to the Cloud and the robots generate full reports on all of their activities, which are stored on the Cloud. Relevant hospital and Netcare stakeholders are able to monitor the activities of each robot in real-time and access full reports at any time.
“Another benefit brought about by the deployment of the robots is that the cleaners responsible for operating this technology have been thoroughly trained in its use and have been able to acquire a new set of skills. This is not a case of robots replacing human labour, but rather of robots empowering their human operators.” 

“Many of those who are admitted to hospital are particularly vulnerable to infection. The aim of our infection prevention and control programmes and the use of technology such as this is to help protect those in our care, as well as visitors, staff members and medical practitioners from any potentially harmful germs including COVID-19. Persons admitted to a Netcare facility can therefore be assured that the hospital’s wards, theatres and other facilities is being disinfected as thoroughly as possible,” concludes Dr Maslo. 
Dr Mpho Ramabulana stresses the importance of early detection of colorectal cancer.
April 11, 2025
Colorectal cancer, one of the most prevalent yet preventable cancers, can develop in the colon or rectum, often starting as small polyps that can quietly become malignant if left unchecked. Dr Mpho Ramabulana, a colorectal surgeon and gastroenterologist at Netcare Akasia Hospital, underscores the life-saving power of vigilance and the importance of early detection.
Cardiologist Dr Robert Routier and cardiothoracic intensive care unit manager Sr Nondumiso Fakude
April 1, 2025
Cardiologist Dr Robert Routier urges the public to check their personal risk factors regularly to help prevent or manage cardiovascular disease.
Obstetrician and gynaecologist Dr Natalie Odell
March 26, 2025
The physical strain pregnancy puts on an expectant mother’s body should not be underestimated. An obstetrician gynaecologist offers her insights for alleviating discomfort and promoting wellbeing with exercise and stretching throughout pregnancy.
Dr Patience Sigwadi
March 19, 2025
Dr Patience Sigwadi, a leading paediatric nephrologist practising at Netcare Unitas Hospital in Centurion, has issued an urgent call for increased focus on skills development to address the escalating kidney disease crisis among children in South Africa.
Paediatric Nephrologist Prof Rajendra Bhimma
March 11, 2025
Paediatric Nephrologist Professor Bhimma was recently awarded the Fellowship to acknowledge his extensive work in research, community-based outreach and teaching of paediatric nephrology, among others.
Prof Bhekifa Dube
March 7, 2025
Netcare congratulates Professor Bhekifa Dube on his invitation to join the European Society for Vascular Surgery's clinical practice guidelines committee. His selection as the only specialist from the continent highlights the significance of this achievement on the global stage.
Rare Disease Day on 28 February 2025
February 28, 2025
The lives of millions of South Africans with a litany of rare diseases can be vastly improved, and even saved, by addressing challenges in identifying, studying and treating their conditions. With Rare Disease Day on the 28th of February 2025, the Rare Diseases Access Initiative (RDAI) is driving an evolution of the country’s healthcare, through innovative strategies to better care for over 4.2million people living with an estimated 7000 rare diseases. “As our healthcare system faces significant changes in the years ahead, it is vital that we also advocate for people living with rare diseases in South Africa, especially those with limited healthcare access,” said Kelly du Plessis, CEO of Rare Diseases South Africa (RDSA), a member of RDAI. “As part of our ongoing research and awareness efforts, RDAI has conducted an initial analysis of the incidence and prevalence of rare diseases within the country.” This research will assist in improving access to healthcare, policy development, and patient advocacy, while giving critical insight into the challenges faced by patients. “According to research, some rare diseases affect fewer than 1 in a million people, while others, such as Down syndrome, cystic fibrosis, and haemophilia, have a more recognisable prevalence,” says Dr. Helen Malherbe, RDAI lead researcher on rare disease prevalence data. “Many conditions are undetected, underdiagnosed or misdiagnosed, with too many having no information available about them at all.” The RDAI was formed in 2019 to promote a more favourable environment for those impacted by rare diseases in South Africa. Participants include Ampath, the Board of Healthcare Funders (BHF), Discovery Health, Genetic Counsellors South Africa (SASHG), the Government Employees Medical Scheme (GEMS), Health Funders Association (HFA), Medihelp, Medscheme, North-West University (NWU), Rare Diseases South Africa (RDSA), the South African Medical Association (SAMA) and The South African Medical Technology Industry Association (SAMED). The Council for Medical Schemes (CMS) participates as an observer. In the same year, Rare Disease International signed a memorandum of understanding with the World Health Organisation leading to an international rare disease policy framework. In 2021, the United Nations General Assembly moved to adopt a resolution recognising 300 million people living with rare diseases worldwide. “A general lack of awareness and delayed diagnosis remain major hurdles for those affected by rare diseases. Policymakers and healthcare stakeholders need to prioritise access to treatment, diagnosis, and support for rare disease patients,” says Bada Pharasi, CEO of IPASA, “Through this initiative, working collaboratively with stakeholders at every level of the healthcare supply chain, we can bring real and meaningful change to those affected, including family members and care givers, through smart and efficient strategies.” The globally agreed definition of a rare disease is any medical condition with a specific pattern of clinical signs, symptoms, and findings that affects fewer than or equal to 1 in 2000 persons in a population. “Most are genetic, and some are inherited and passed down in families,” Malherbe says. “Some affect only the patient’s genetic recipe, while others may be acquired during life due to infection, trauma, or environmental effects. For many, the cause is still unknown. “These conditions mainly affect children, as they are largely incurable and many are life-threatening. Some require specialised and co-ordinated care, some have limited and expensive treatment options, while others have no information or effective treatments at all,” she adds. The RDAI is calling for a patient-centred care model built on equitable access, transparency and efficiency. Naturally, this model calls for the open participation of patients, the healthcare industry, health professionals, and the Government. “The most critical elements are robust diagnosis standards, improved access to treatment, data collection and management, co-ordination of care, measurement of outcomes and ongoing collaborative research,” du Plessis says. “We need to establish rare disease advisory committees, map gaps and opportunities, establish system requirements, create a roadmap and plan a phased implementation with clear timelines.” The RDAI states that these policy development steps would be a start in quantifying the disease burden and defining standards of care. This would be followed by building and strengthening the capacity to facilitate appropriate diagnosis, treatment, continuity and data monitoring. Thoneshan Naidoo, Chief Executive Officer of the Health Funders Association noted that, “We appreciate the unique opportunity provided by RDAI which enables stakeholders across the industry to work together and identify strategies that improve equitable access to the appropriate diagnosis, treatment and healthcare services for rare disease patients, in an affordable and sustainable manner, taking account of the other pressing needs across the healthcare system.” “True innovation in healthcare is only possible through partnerships and joint advocacy efforts that raise awareness and improve access to treatment. Our long-term goal is the development of a rare diseases policy framework and guidelines for coordinated care,” says Pharasi. “Our members are united in the commitment to unlocking improved patient outcomes and improving access to services and robust health needs assessment facilities.” he concludes. About RDAI The Rare Diseases Access Initiative (RDAI) is dedicated to advocating for improved healthcare access, policy development, and patient support for those affected by rare diseases in South Africa. The initiative brings together key healthcare stakeholders, including pharmaceutical associations, funders, genetic specialists, and patient advocacy groups, to drive impactful change. About RDSA Founded in 2013, Rare Diseases South Africa (RDSA) is a non-profit organisation advocating to ensure that people living with rare diseases and congenital disorders experience greater recognition, support, improved health service and better overall quality of life. Started out of personal need following the diagnosis of organisation founder, Kelly du Plessis' son, it became evident that there was a lack of awareness and support for rare diseases in general in South Africa. About IPASA The Innovative Pharmaceutical Association South Africa (IPASA) is a voluntary trade association representing 24 leading pharmaceutical companies committed to research, development, and innovation. Our mission is to drive healthcare advancement by advocating for policies that improve patient access to safe, high-quality, and affordable medicines.
Gastroenterologist Dr Barbara Makumbi explains the toll acid reflux can take on your health
February 26, 2025
Gastroenterologist Dr. Barbara Makumbi discusses common risk factors and offers tips for managing reflux and the longer-term condition known as gastroesophageal reflux disease (GORD).
Netcare St Anne’s Hospital emergency department now has both trauma and emergency  specialists.
February 19, 2025
From treating trauma injuries caused by wildlife, road accidents and sports, to heart attacks, stroke, or the sudden onset of other concerning medical symptoms – the emergency department at Netcare St Anne’s Hospital never sleeps.
Making sense of self-harm
February 10, 2025
As many as one in ten teenagers may self-harm, often in secret, concealing the scars or evidence of their injuries. As Teen Suicide Prevention Week approaches, Netcare Akeso is highlighting the often-hidden struggle of self-harm among young people.
More Posts
Share by: